AAPS PharmSciTech

, Volume 6, Issue 3, pp E523–E526 | Cite as

In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: A technical note

Article

Conclusions

In vivo ocular availability of ketorolac was evaluated following ocular instillation of aqueous, oil, and ointment formulations to normal corneas of rabbits and monitoring ketorolac concentration in aqueous humor by HPLC. Compared with aqueous drop, sesame and soybean oil drops of ketorolac provided higher ocular availability followed by ophthalmic ointment. The ointment formulation provided maximum sustained effect. Ketorolac aqueous drop with BAC and EDTA improved the rate of ocular absorption though not the extent.

Keywords

Aqueous Humor Ketorolac AAPS PharmSciTech Ophthalmic Solution High Performance Liquid Chro 

References

  1. 1.
    Herch PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing.Arch Ophthalmol. 1990;108:577.Google Scholar
  2. 2.
    Cooper CA, Bergamini MVW, Leopold IH. Use of flurbiprofen to inhibit corneal neovascularization.Arch Ophthalmol. 1980; 98:1102–1105.Google Scholar
  3. 3.
    Kraff MC, Sanders DR, Mcguigan L, Rannan MG. Inhibition of blood-aqueous humor barrier breakdown with diclofenac: a fluorometric study.Arch Ophthalmol. 1990;108:380–383.Google Scholar
  4. 4.
    Searle AE, Pearce JL, Shaw DE. Topical use of indomethacin on the day of cataract surgery.Br J Ophthalmol. 1990;74:19.CrossRefGoogle Scholar
  5. 5.
    Mahoney JM, Waterbury LD. (±) 5 benzoyl-1,2-dihydro-3H pyrrolo [1,2a] pyrrole-1-carboxylic acid (RS 37619]: a non irritating ophthalmic anti-inflammatory agent.Invest Ophthalmol Vis Sci. 1983;24:151–159.Google Scholar
  6. 6.
    Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on post surgical blood aqueous barrier.Arch Ophthalmol. 1998;106:480–483.Google Scholar
  7. 7.
    Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation, after cataract surgery: a randomized vehicle—controlled clinical trial.Am J Ophthalmol. 1999;127:253–259.CrossRefGoogle Scholar
  8. 8.
    Solomen KD, Cheetham JK, Degryse R, Brint SF, Rosenthal A. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery.Ophthalmology. 2001;108:331–337.CrossRefGoogle Scholar
  9. 9.
    Fraser-Smith EB, Mathews TR. Effect of ketorolac onCandida albicans ocular infection in rabbit.Arch Ophthalmol. 1987; 105:264–267.Google Scholar
  10. 10.
    Fraser-Smith EB, Mathews TR. Effect of ketorolac onPseudomonas aeruginosa ocular infection in rabbits.J Ocul Pharmacol. 1988; 4:101–109.CrossRefGoogle Scholar
  11. 11.
    Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudoaphakic cystoid macular edema.Am J Ophthalmol. 1987;103:479–486.Google Scholar
  12. 12.
    Price FW Jr, Price MO, Zeh W, Dobbins K. Pain reduction after laser in situ keratomisleusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo controlled trial.J Refract Surg. 2002;18:140–144.Google Scholar
  13. 13.
    Malhotra M, Majumdar DK. Effect of preservative, antioxidant and viscolizing agents on in vitro transcorneal permeation of ketorolac tromethamine.Indian J Exp Biol. 2002;40:555–559.Google Scholar
  14. 14.
    Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment.Indian J Exp Biol. 1997;35:1324–1330.Google Scholar
  15. 15.
    Ling TL, Combs DL. Ocular bioavailability and tissue distribution of [14C] ketorolac tromethamine in rabbits.J Pharm Sci. 1987; 76:289–294.CrossRefGoogle Scholar
  16. 16.
    Madhu C, Rix PJ, Shackleton MJ, Nguyen TG, Tang-Liu DDS. Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillations to normal and de-epithelized corneas of rabbits.J Pharm Sci. 1996;85:415–418.CrossRefGoogle Scholar
  17. 17.
    Pharmacopoeia of India. 2nd ed. Delhi, India: Government of India, Ministry of Health and Family Welfare; 1970:203.Google Scholar
  18. 18.
    Fu RC, Lidgate DM. In vitro rabbit corneal permeability study of ketorolac tromethamine.Drug Dev Ind Pharm. 1986;12:2403–2430.CrossRefGoogle Scholar
  19. 19.
    Grass GM, Wood RW, Robinson JR. Effects of calcium chelating agents on corneal permeability.Invest Ophthalmol Vis Sci. 1985;26:110.Google Scholar
  20. 20.
    Kennah HE, Higney S, Laux PE, Dorko JD, Barrow CS.Fundam Appl Toxicol. 1989;12:258–268.CrossRefGoogle Scholar
  21. 21.
    Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability 1. Evaluation of fluorometholone.J Pharm Sci. 1975;64:931.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2005

Authors and Affiliations

  1. 1.Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and ResearchFormerly College of Pharmacy (University of Delhi)New DelhiIndia

Personalised recommendations